Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Nateraâs complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications. Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Companyâs own robust laboratory processes thousands of genetic tests per month. Nateraâs goal is to transform the way people â both providers and patients â respond to and manage genetic diseases. Source
No articles found.
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Acceleron is dedicated to the discovery and development of innovative, life-changi...
Acceleron is dedicated to the discovery and dev...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
At Delee, we aim to radically change the way cancer is detected, monitored and tre...
At Delee, we aim to radically change the way ca...
BioSig Technologies is a medical device company developing a proprietary technolog...
BioSig Technologies is a medical device company...
Semler Scientific, Inc. is an emerging medical risk-assessment company whose diagn...
Semler Scientific, Inc. is an emerging medical ...
Join the National Investor Network and get the latest information with your interests in mind.